In a 38‑year‑old woman with biopsy‑proven pulmonary sarcoidosis presenting with presyncope, palpitations, and second‑degree atrioventricular block (Mobitz type II), what cardiac manifestation is most commonly associated with sarcoidosis, why is it prevalent, and what immediate diagnostic and therapeutic steps should be taken?

Cardio-Rheumatology Overlap Quiz Question

Clinical Scenario:

A 38-year-old woman with biopsy-proven pulmonary sarcoidosis presents to the emergency department with a 2-week history of intermittent palpitations and two episodes of presyncope. Her ECG reveals second-degree atrioventricular block, Mobitz type II, with a heart rate of 45 bpm. She denies chest pain but reports mild dyspnea on exertion.

Questions to address:

1. What is the most common cardiac manifestation of sarcoidosis, and why does it occur with such frequency in this disease?

2. Given her presentation with Mobitz type II AV block, explain why atropine would be ineffective in this patient and what immediate therapeutic intervention is indicated.

3. Outline the complete diagnostic workup needed to evaluate for cardiac sarcoidosis in this patient, including which imaging modality has the highest sensitivity for detecting cardiac involvement.

4. What is the definitive long-term management strategy for this patient's conduction abnormality, and what additional cardiac evaluation must be performed before hospital discharge?

---

Model Answer Guide:

Question 1: Most Common Cardiac Manifestation

Conduction system abnormalities, particularly atrioventricular block, represent the most common cardiac manifestation of sarcoidosis 1, 2. This occurs because non-caseating granulomas preferentially infiltrate the basal interventricular septum and conduction system, causing inflammation and subsequent fibrosis of the His-Purkinje system 3, 4. The granulomatous infiltration disrupts normal electrical conduction pathways, with the block typically occurring below the AV node (infranodal), making it particularly dangerous due to risk of progression to complete heart block 5.

Approximately 30% of patients under 60 years presenting with unexplained high-degree AV block are ultimately diagnosed with cardiac sarcoidosis 3. The basal septum location explains why these blocks are typically Mobitz type II or complete heart block rather than Mobitz type I, as the pathology affects the His bundle and bundle branches rather than the AV node itself 6.

Question 2: Why Atropine is Ineffective & Immediate Management

Atropine will be ineffective because Mobitz type II block occurs below the AV node within the His-Purkinje system, where vagal innervation is absent 5. Atropine works by reversing cholinergic effects at the AV node level but cannot influence infranodal conduction tissue 5.

Immediate management requires transcutaneous pacing (TCP) as a temporizing measure while preparing for transvenous pacemaker placement 5. Given her symptomatic presentation with presyncope, this represents a high-risk situation where Mobitz type II can progress unpredictably to complete heart block 5. The 2010 AHA guidelines specifically identify Mobitz type II as requiring pacing rather than pharmacologic intervention 5.

Question 3: Complete Diagnostic Workup

The diagnostic evaluation must include:

Initial screening tests (performed in all sarcoidosis patients even without symptoms) 7:

• 12-lead ECG - sensitivity 9% but specificity 97% for cardiac involvement 7
• Transthoracic echocardiography (TTE) - sensitivity 25%, specificity 95% 7
• 24-hour Holter monitoring - sensitivity 50%, specificity 97% 7

Advanced imaging when screening is positive or high clinical suspicion:

• Cardiac MRI with late gadolinium enhancement (LGE) - This is the most sensitive non-invasive test, showing characteristic non-ischemic epicardial-to-mid-myocardial enhancement pattern, particularly in the basal septum, inferior wall, and lateral wall 8. The extent of LGE is an important prognostic factor 4.
• FDG-PET imaging - Detects active inflammation to guide immunosuppression therapy 4

Laboratory evaluation:

• Serum angiotensin-converting enzyme (ACE) levels - often markedly elevated (>90 U/L) 8

Tissue diagnosis consideration:

• Endomyocardial biopsy has low sensitivity due to patchy involvement but provides definitive diagnosis when positive 9, 3

Question 4: Definitive Long-term Management

This patient requires permanent pacemaker implantation 6. Mobitz type II AV block in the setting of cardiac sarcoidosis is a Class I indication for permanent pacing, as it is symptomatic, infranodal, and has high risk of progression to complete heart block 6, 1.

Critical additional evaluation before discharge:

1. Assess for ventricular arrhythmia risk and need for ICD:

   • Evaluate left ventricular ejection fraction (LVEF) via echocardiography
   • If LVEF <35%, consider ICD with or without cardiac resynchronization therapy (CRT) rather than pacemaker alone 9
   • Extent of myocardial LGE on cardiac MRI predicts arrhythmic risk 4

2. Initiate immunosuppressive therapy:

   • Corticosteroids (prednisone/prednisolone) are first-line treatment for clinically manifest cardiac sarcoidosis 2, 4
   • FDG-PET imaging guides therapy by detecting active inflammation 4

3. Screen for other organ involvement:

   • High-resolution chest CT for pulmonary assessment
   • Ophthalmologic examination
   • Complete blood count (lymphopenia occurs in 27-55% of cases) 7

Critical pitfall: Do not delay pacemaker placement for immunosuppression to take effect. The conduction abnormality requires immediate device therapy, while immunosuppression prevents disease progression 2, 4. Approximately 5% of sarcoidosis patients have clinically manifest cardiac involvement, but autopsy studies suggest 20-50% have some degree of cardiac infiltration 9, 3. Cardiac sarcoidosis is the second leading cause of death in sarcoidosis patients after pulmonary involvement 3, making aggressive early management essential for mortality reduction.